[Early phase II study of S-1 in patients with advanced head and neck cancer. S-1 Cooperative Study Group (Head and Neck Working Group)].

@article{Inuyama1998EarlyPI,
  title={[Early phase II study of S-1 in patients with advanced head and neck cancer. S-1 Cooperative Study Group (Head and Neck Working Group)].},
  author={Yukio Inuyama and Atsushi Kida and Mamoru Tsukuda and Naoyuki Kohno and Bunsuke Satake},
  journal={Gan to kagaku ryoho. Cancer & chemotherapy},
  year={1998},
  volume={25 8},
  pages={1151-8}
}
In developing new anticancer agents, the most important thing is the balancing of antitumor activity and toxicity. To achieve high activity and low toxicity, S-1 was designed, in which tegafur, prodrug of 5-FU, was combined with two classes of modulators. CDHP, inhibitor of 5-FU degradation in liver and Oxo, inhibitor of 5-FU phosphoribosylation in digestive tract, respectively. This cooperative study with 15 nation-wide institutes was conducted to evaluate the antitumor activity and toxicity… CONTINUE READING

Connections & Topics

Mentioned Connections BETA
To achieve high activity and low toxicity , S-1 was designed , in which tegafur , prodrug of 5-FU , was combined with two classes of modulators .
Out of 26 patients , CR was achieved in 1 and PR in 11 with a response rate of 46.2% , while adverse events of grade 3 were as follows : hemoglobinemia ( 7.7% ) , leukocytopenia , neutropenia , stomatitis and anorexia ( 3.8% ) , each .
All Topics